The financial results for Anteris for the quarter ended June 30, 2026, are presented below. All amounts in $ refer to U.S. dollars.
Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway
Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway Proactive uses images sourced from Shutterstock Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) ...
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201Completed $100 million underwritten offering, including $40 million ...
You’re reading The TNR Blue Book. Get daily scoops, strategy, and developments inside the liberal ideas factory delivered right to your inbox. Sign up for free. Inside Washington The big question in ...
The West Monroe–West Ouachita Chamber of Commerce announced it is promoting an upcoming regional workshop designed to equip ...
New preclinical research has made a key discovery regarding the spread of ovarian cancer after chemotherapy. Fructose may play a role, it found.
Regenxbio surged on milestone revenue and EPS beat, with a $313M cash runway to 2027. Click here to read my most recent analysis.
First, keep students in school, then guide them towards skills and employment. It is along this trajectory that Campania is trying to transform one of its historical weaknesses—its educational ...
Good afternoon, and welcome to the Mobia Medical Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that today's conference is being recorded. I would now like to turn ...
A major study published this spring in JAMA Network Open analyzed outcomes for nearly 16,000 Medicare beneficiaries and found that hospital-at-home patients had dramatically lower in-hospital ...
Tribune Online on MSN
Agric stakeholders seek paradigm shift in scaling proven innovations
Africa’s leading agricultural development organisations have called for a fundamental shift in how agricultural innovations are scaled, arguing that the continent’s greatest challenge is no longer the ...
IMMUNO-BIOMAP targets the clinical uncertainty around who benefits from first-line immunotherapy, who experiences early failure, and whether fixed two-year treatment durations are necessary in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results